Podcast · Tech & Science

EHA Unplugged

by European Hematology Association · English · Tech & Science

In these EHA-produced podcasts, experts share with you their hematology knowledge and stories. With "EHA Unplugged" we would like to give you the opportunity to unplug from your computer screen, while still learning, by listening to interviews, clinical cases, monologues, and more.

New episodes: Weekly
Typical length: 20 min
Latest: 9 Oct 2026
Language: English

Latest episode

9 Oct 2026 · 12 min

How Experts Treat Hodgkin Lymphoma

Stay up to date with the latest EHA guidelines on Hodgkin lymphoma. In this episode of EHA Unplugged , key guideline authors Prof. Dennis Eichenauer and Prof. Igor Aurer discuss the evidence reshaping the management of classic Hodgkin lymphoma. The discussion highlights the guideline’s central shift: the integration of targeted therapies—brentuximab vedotin and PD-1 inhibitors such as nivolumab—into frontline treatment. The experts explain updated approaches to staging and risk assessment, PET-guided treatment in early-stage disease, BrECADD for younger patients with advanced disease, and…

Play episodeWhatsApp Download

Earlier episodes 29 most recent

S6 · E27 · 2 Oct 2026 · 15 min
How to Improve Equity and Inclusion in Hematology: EHA2026 Diversity, Equity and Inclusion Award
In this episode, Prof Gianluca Gaidano, recipient of the EHA2026 Diversity, Equity and Inclusion Award, explores how promoting equity, inclusion, and access to care has shaped his work within EHA and beyond. He reflects on educational initiatives in underrepresented regions, including Africa, the Middle East, Asia, and South America, and explains how international collaborations can help expand access to medical knowledge, advanced diagnostics, and innovative therapies. The discussion explores the difference between drug availability and true patient access, the role of education and patient…
S6 · E26 · 25 Sep 2026 · 21 min
Advancing Adult ALL Care in Europe: EHA2026 Clinical Excellence Award
In this episode, Professor Josep-María Ribera, recipient of the EHA2026 Clinical Excellence Award, reflects on his career dedicated to adult acute lymphoblastic leukemia (ALL) and the advances that have transformed patient outcomes. He discusses the evolution of treatment for Philadelphia chromosome-positive ALL, from poor survival rates to highly effective targeted and immunotherapy-based approaches, and explains how tyrosine kinase inhibitors, blinatumomab, and chemotherapy-sparing strategies are reshaping care. The discussion also explores the growing role of measurable residual disease…
S6 · E25 · 22 Sep 2026 · 23 min
Refining Transplantation and Cellular Therapy: Insights from 2026 Young EHA Award Winner Nico Gagelmann
In this episode, Dr Nico Gagelmann, recipient of the 2026 Young EHA Award, discusses his career in stem cell transplantation and the values that have shaped his work. He explains how multidisciplinary care, patient selection, graft-versus-host disease prevention, and conditioning strategies can help improve transplant outcomes. The discussion also explores the role of real-world evidence in identifying best practices and supporting efforts to harmonize transplantation approaches across centres. Dr Gagelmann also highlights the evolving role of CAR T-cell therapy, ongoing disparities in…
S6 · E24 · 18 Sep 2026 · 22 min
What Can We Learn About AML from Clonal Haematopoiesis? | EHA 2026 Research Excellence Award
In this episode, Prof George Vassiliou, recipient of the 2026 EHA Research Excellence Award, discusses how his research has advanced our understanding of clonal haematopoiesis and its relationship to acute myeloid leukaemia (AML). He explains how blood stem cells evolve over time, why specific driver mutations promote clonal expansion, and how genetic profiles can help identify individuals at low, intermediate, or high risk of developing myeloid malignancies. The discussion also explores efforts to translate these discoveries into clinical prevention strategies. Prof Vassiliou highlights…
S6 · E23 · 15 Sep 2026 · 21 min
Improving MPNs management: EHA2026 Lifetime Achievement Award
In this episode, EHA 2026 Lifetime Achievement Award recipient Prof Claire Harrison reflects on a career dedicated to advancing the understanding and management of myeloproliferative neoplasms (MPNs). She reviews the major scientific and clinical developments she has witnessed over more than two decades, including the discovery of JAK2, MPL and CALR mutations, the evolution of diagnostic criteria, and the emergence of targeted therapies for MPNs. The discussion explores landmark studies that helped shape current clinical practice, including PT-1, COMFORT-II and MAJIC-PV, as well as the…
S6 · E21 · 9 Sep 2026 · 18 min
CAR T Toxicities in Focus: What We Have Learned from Registry Data
In this episode, Dr Annalisa Ruggeri discusses how registry data are helping clinicians better understand, monitor and manage CAR T-related toxicities. She explains how insights from more than 16,000 patients recorded in the European Bone Marrow Transplant Registry (EBMT), have helped improve early toxicities such as cytokine release syndrome (CRS) and ICANS awareness and management as well as helped recognise and address longer-term effects. She further explores the growing understanding of immune effector cell-associated hematotoxicity (ICAHT) and the importance of risk prediction and…
S6 · E20 · 6 Sep 2026 · 21 min
Life After YERM: How the Young EHA Research Meeting Shaped Careers
In the final episode of our mini-series celebrating the 10th anniversary of the Young EHA Research Meeting (YERM), we explore how the meeting acts as a powerful launching pad for scientific careers. We talk to 2018 YERM speakers Dr. Lorena Arranz and Dr. Mattias Carlsten to hear about their experiences presenting their research at YERM. Looking back on their journeys, they share valuable advice and lessons learned at YERM to help guide today's early-career researchers. Guests: Dr Mattias Carlsten, Karolinska Institutet and Karolinska University Hospital, Sweden Dr. Lorena Arranz, University…
S6 · E19 · 6 Sep 2026 · 19 min
Discover YERM: The Young EHA Research Meeting and Your Place in It
Welcome to our mini-series celebrating the 10th anniversary of the Young EHA Research Meeting (YERM) with an introduction to its history and mission. We sit down with co-founder Prof Ruud Delwel and current organizer Prof Marlies Vanden Bempt to discuss how YERM is tailored to empower early-career researchers. Together, we reflect on a decade of growth and share their vision for the future of YERM. Guests: Prof Ruud Delwel, Erasmus Medical Centre, The Netherlands Prof Marlies Vanden Bempt, KU Leuven, Belgium Host: Rhiannon Newman, MSc, University of Helsinki and Young EHA committee Learn…
S6 · E18 · 28 Aug 2026 · 22 min
CAR-T for Pediatric B-ALL: Expert Tips
In this episode, Prof André Baruchel discusses the role of CAR T-cell therapy in children with B-cell acute lymphoblastic leukemia (B-ALL). He reviews current indications for CAR T-cell treatment, including relapsed and refractory disease, and explores whether CAR T could move earlier in the treatment pathway. The discussion also examines how CAR T-cell therapy compares with transplantation, blinatumomab, and other salvage strategies, as well as the factors that influence long-term outcomes and relapse risk. The conversation highlights key questions surrounding the role of allo-HSCT in the…
S6 · E17 · 25 Aug 2026 · 21 min
Getting Patients to CAR T: Referral Systems in Europe
In this episode of EHA Unplugged, Prof Marion Subklewe discusses one major challenge facing CAR T-cell therapy in Europe: ensuring that eligible patients are referred for treatment. She explains how access has improved since the first CAR T-cell approvals, but highlights that many eligible patients still do not receive these potentially curative therapies. The discussion explores differences between European healthcare systems, barriers to referral, and persistent misconceptions about patient eligibility. Prof Subklewe advocates for structured referral pathways and multidisciplinary boards…
S6 · E16 · 21 Aug 2026 · 21 min
Outpatient CAR T in Europe: Lessons from Barcelona
In this episode, Dr Alexandra Martínez Roca and Dr Beatriz Merchán Muñoz discuss how their team at Hospital Clínic de Barcelona has developed a fully outpatient programme for CAR T-cell therapy. They explain the evolution of their at-home programme, from outpatient transplantation and supportive care to outpatient CAR T administration, and describe the key clinical and logistical requirements for patient selection. The discussion explores caregiver training, monitoring for cytokine release syndrome and neurotoxicity, and the importance of dedicated multidisciplinary teams. The guests also…
S6 · E15 · 18 Aug 2026 · 18 min
Smarter CARs: Using AI to Improve Chimeric Antigen Receptor Design
Artificial intelligence is opening new possibilities in the design of next-generation immunotherapies. In this episode of EHA Unplugged, Dr Andrea Schmidts discusses how AI-driven approaches are reshaping the development of chimeric antigen receptor (CAR) T-cell therapies, particularly at the design stage of the CAR receptor binding domains. Dr Schmidts explains how structure-based AI models can generate entirely new protein binders, moving beyond the traditional reliance on monoclonal antibody–derived fragments. The conversation explores how these tools enable large-scale exploration of CAR…
S6 · E14 · 17 Aug 2026 · 19 min
What is Real-World Evidence Revealing About CAR T Therapy?
In this episode, Prof Benoit Tessoulin examines how real-world evidence from the French DESCAR-T registry is expanding our understanding of CAR T-cell therapy beyond clinical trials. He explains how the registry captures data from patients considered for CAR T-cell treatment, including those who do not ultimately receive therapy, and explores what these data reveal about patient selection, treatment outcomes, bridging therapy, and comparisons between different CAR T-cell products. The discussion also examines how real-world populations differ from clinical trial cohorts, in what measure…
S6 · E13 · 31 Jul 2026 · 23 min
Hematology Portraits: Prof Frank Leebeek
In this episode Prof. Frank Leebeek reflects on his career in hematology, highlighting a lifelong commitment to bridging clinical practice and research. From his early interest in fibrinolysis during medical school to his current role as Chair of the Department of Hematology at Erasmus Medical Center and Board member at EHA, Prof. Leebeek shares how a dual commitment to research and patient care has shaped his path. The conversation explores key milestones in bleeding disorders research, including large-scale studies on von Willebrand disease that helped improve awareness, diagnosis, and…
S6 · E12 · 16 Jul 2026 · 19 min
How to Start a Clinical Trial?
What does it take to design and lead a clinical trial in hematology? In this episode of EHA Unplugged , Prof. Elias K. Mai shares his experience transitioning from clinical practice to becoming a principal investigator, and how the EHA Clinical Research Training in Hematology (CRTH) program helped shape his path. Prof. Mai reflects on the practical and often underappreciated challenges of clinical trial design—from budgeting and statistical planning to ethical considerations and regulatory requirements. He highlights the importance of mentorship and peer networks, as well as the need for…
S6 · E11 · 3 Jul 2026 · 36 min
How Experts Treat Multiple Myeloma
In this episode, Prof. Pieter Sonneveld is joined by Prof. Meletios Dimopoulos and Prof. Evangelos Terpos to discuss the updated EHA–EMN (European Myeloma Network) guidelines for the diagnosis, treatment and follow-up of multiple myeloma. The conversation explores how recent therapeutic advances—including 14 newly approved treatment regimens, CAR T-cell therapies, bispecific antibodies and antibody-drug conjugates—have reshaped the treatment landscape and informed the latest recommendations. The experts discuss the integration of novel prognostic tools such as minimal residual disease (MRD),…
S6 · E10 · 22 Jun 2026 · 23 min
Where Are We Now With Immunotherapy in Multiple Myeloma?
Explore the latest advancements in immunotherapies for multiple myeloma, including CAR T-cell therapy, bispecific antibodies, and antibody-drug conjugates. In this episode, Dr. Paula Rodriguez Otero discusses the strategic sequencing of BCMA and explains why CAR-T cells should often precede bispecific antibodies to maximize efficacy while managing toxicity. The episode highlights the potential for these therapies to replace transplants by inducing deep, durable responses. Dr. Otero also explores new targets like GPRC5D, offering insights into future treatment possibilities. Guests: Dr Paula…
S6 · E9 · 1 Jun 2026 · 20 min
Menin Inhibitors to Treat Acute Myeloid Leukemia (AML)
Get up to date on menin inhibitors, an emerging class of targeted therapies for acute myeloid leukemia (AML). Menin is a key component of the KMT2A (lysine methyltransferase 2A, formerly MLL1) complex, which plays a critical role in gene regulation, development, and cell cycle control. Small-molecule menin inhibitors have shown particular promise in KMT2A-rearranged (KMT2Ar) and NPM1-mutated AML, with two agents already receiving FDA breakthrough therapy designation. In this episode, Dr Scott Armstrong and Prof Marc Raaijmakers explore the scientific rationale behind menin inhibition,…
S6 · E8 · 13 May 2026 · 11 min
How Experts Treat HIV-associated Lymphomas
Get up to date with the EHA–ESMO guidelines on Human immunodeficiency virus (HIV)-associated Lymphomas. In this episode, Prof. Kai Hubel, a key author of the guidelines, explains the importance of having dedicated recommendations for patients with HIV-associated lymphomas. He begins by discussing the prevalence of lymphomas in people living with HIV, then highlights that the modern CART HIV treatment should be combined with the lymphoma treatments. This interview further provides practical guidance to navigate these detailed recommendations that cover key lymphoma subtypes including DLBCL,…
S6 · E7 · 7 May 2026 · 19 min
Hematology Portraits: Associate Prof Meritxell Alberich Jordà
Join Meritxell Alberich Jordà, an EHA Board member and a principal investigator from Prague, as she shares her journey to becoming a recognised research scientist in hematology, and the role EHA has played along the way. Her lab studies hematopoietic and leukemic stem cells, focusing on how disruptions in transcriptional regulation and inflammatory signalling drive the development and persistence of acute myeloid leukemia. Meri reflects on how her early research interests evolved over time, how key career decisions shaped the questions she pursues today, and what she finds most rewarding…
S6 · E6 · 23 Apr 2026 · 18 min
How Experts Treat Large B-cell Lymphoma (LBCL)
Get up to date with the latest EHA Clinical Practice Guidelines for Large B-cell lymphoma (LBCL) ( ⁠ Large B‐cell lymphoma (LBCL): EHA Clinical Practice Guidelines for diagnosis, treatment, and follow‐up - Thieblemont - 2025 - HemaSphere - Wiley Online Library). ⁠ Prof Catherine Thieblemont and Prof Marie José Kersten, two key authors of the guidelines, walk us through the recommendations for Large B-cell lymphoma, covering diagnosis, treatment, and follow-up. Gain insights into key diagnostic considerations including staging, biopsy techniques and the importance of molecular testing. Our…
S6 · E5 · 10 Apr 2026 · 25 min
Connecting Hematology Research and Real Life: Peter Kapitein
In this episode of EHA Unplugged, patient advocate Peter Kapitein discusses the importance of connecting patients, researchers, and clinicians to accelerate cancer research and treatment. He shares insights from his work with Inspire2Live, focusing on collaboration, data ownership, affordability, and global access to innovative therapies. Guest: Peter Kapitein Host: Isabel Olivera Martinez, PhD Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. ⁠⁠⁠⁠⁠⁠Provide Feedback⁠⁠⁠⁠⁠⁠ Would you like to explore more eLearning or podcasts? Please…
S6 · E4 · 3 Apr 2026 · 30 min
How Experts Treat Peripheral T- and NK-cell Lymphomas
Get up to date with the latest ESMO-EHA guideline for Peripheral T- and natural killer-cell lymphomas ( Peripheral T‐ and natural killer‐cell lymphomas: ESMO‐EHA Clinical Practice Guideline for diagnosis, treatment, and follow‐up - d'Amore - 2025 - HemaSphere - Wiley Online Library ) Prof Francesco D'Amore (Aarhus University, Denmark) and Prof Massimo Federico (University of Modena and Reggio Emilia, Italy). In this episode, two key authors of the guidelines walk us through the recommendations for these rare, biologically diverse, and often aggressive- peripheral T cell and NK cell…
S6 · E3 · 16 Mar 2026 · 17 min
Hematology Portraits: Prof Konstanze Döhner
Join EHA President Prof Konstanze Döhner from University Hospital Ulm in Germany as she discusses her deep interest in hematology, both in research and in the clinics. Listen as Prof. Döhner shares why she decided to focus on Acute Myeloid Leukemia (AML) and myeloproliferative neoplasms (MPNs) in her career as a medical doctor, a researcher and a educator. Tune in to hear Prof. Döhner describe her journey to becoming the EHA president and her reflections on the current challenges in the hematology field and the solutions she proposes to address those. Guest: Prof Konstanze Döhner, University…
S6 · E2 · 27 Feb 2026 · 27 min
How Blood Cells Age: From Stem Cells to Clones (with Dr Michael Milsom)
In this episode, Dr Michael Milsom discusses how thehematopoietic system aging is a complex process with multiple causes. Dr Milsom proposes a more holistic view of the driving mechanisms of hematopoietic andimmune aging that does not focus solely on HSCs. He describes how inflammation‑driven stem cell activation and proliferation cause functional attrition and clonalselection of HSCs, contributing to clonal hematopoiesis. Learn about the mechanisms of blood cells aging andpotential interventions to slow down the process. Guest: Dr Michael Milsom Head of the Division of Experimental…
S6 · E1 · 6 Feb 2026 · 16 min
How Experts Treat Mantle Cell Lymphoma (with Prof Mats Jerkeman)
Get up to date with the latest EHA-EU guideline for Mantle Cell Lymphoma ( EHA–EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma - Jerkeman - 2025 - HemaSphere - Wiley Online Library ) with Prof Mats Jerkeman (Lund University, Sweden). In this episode, he explains how biological risk factors, particularly TP53 mutations and proliferation rate, inform patient stratification. He reviews evolving treatment sequencing, including the expanding role of BTK inhibitors (such as ibrutinib) in first-line regimens. He further discusses the management relapsed/refractory MCL,…
S4 · 30 Jan 2026 · 12 min
Life After CAR T-cell Therapy: Jonathan Clark’s Journey with Mantle Cell Lymphoma and the Future of Patient Advocacy
[This is a Rerelease. Episode first published on July 19, 2024.]Join us for a conversation with Jonathan Clark, a patient advocate who has been in remission for over five years after receiving CAR T-cell therapy for Mantle Cell Lymphoma. Jonathan shares his journey from relapse to recovery, detailing the challenges and triumphs of this cutting-edge treatment from a patient’s perspective. With host Dr. Sarah de Vlieger, they discuss his motivation for sharing his story and the profound physical and psychological impacts of long-term remission. Jonathan also talks about managing long-term side…
S4 · 23 Jan 2026 · 16 min
The Role of Artificial Intelligence in Hematology (featuring Dr Gregor Hormann)
[This is a Rerelease. Episode first published on November 22, 2024.]Join us in this podcast episode to get a glimpse of what the future holds in the big field of innovation in hematology. With the help of our host, Dr Gregor Hormann (MLL Munich Leukemia Laboratory, Germany), you will be taken on a journey toward a future that is already here. Dr Hormann will discuss the many potentials of AI in hematology and oncology, including the automated integrated diagnostic tools, from morphology to chromosomal banding analysis in a few minutes, new classification algorithms, and innovative large…
S4 · 16 Jan 2026 · 13 min
How Does Climate Change Affect Hematology Practice? (with Dr Stephen Hibbs)
[This is a Rerelease. Episode first published on November 1, 2024.] Join us for an engaging episode with Dr. Stephen Hibbs from Queen Mary University of London as he discusses the environmental impacts of hematology. Alongside our host Dr. Sarah de Vlieger, they explore how climate change is already affecting hematology, emphasizing that these effects are being felt now rather than in the future. The conversation highlights how climate change alters aspects of hematology practice, such as the risk of transfusion-transmitted infections due to evolving disease vectors. Dr. Hibbs describes also…

About EHA Unplugged

EHA Unplugged is a English tech & science podcast from European Hematology Association. Melo plays each episode straight from the publisher's own feed — no ads added, no account needed — and remembers where you stopped, in this browser only.

Publisher: European Hematology Association
Language: English
Category: Tech & Science
New episodes: Weekly
Typical length: 20 min
Latest episode: 9 Oct 2026
Feed: RSS — paste into any podcast app
Apple Podcasts: podcasts.apple.com/podcast/id1583943470
Rights: European Hematology Association

RSS feed Apple Podcasts

More English tech & science

Take it with you

The Melo app keeps playing with the screen off, works in the car and on your watch, wakes you to your station, and browses the whole catalogue offline. Free, no ads, no account.